Four Patient groups of Nagaland filed a Public Interest Litigation(PIL) at the Gauhati High Court, Kohima Bench on the 18th September 2018 on grounds demanding roll out of “prevention and treatment programs for Hepatitis C (HCV) in Nagaland” against the Nagaland Government and the Union of India.
The Asian Network of People who Use Drugs (ANPUD) is a regional community network committed towards advocating for equal rights and opportunities for people who use drugs. This statement is issued to observe the World Hepatitis Day 2018 and to bring our issues and needs into attention of broader stakeholders.
The world is far more progressive or regressive than the CND deliberations – but it is not what member states are allowed to see, hear and speak. It reminded us of the Gandhi’s three monkeys – See no evil, Hear no evil and Speak no evil. It is time to put people who use drugs, evidence and human rights at the center.
People who use drugs community have been significantly contributing towards achieving the Sustainable Development Goals and Targets despite the hostile context fueled by the criminalizing drug laws and policies. The statement is the truth that everyone needs to know about the diverse roles people who use drugs play in making our society better.
The five policy briefs were developed by the Thai Treatment Action Group (TTAG). The briefs are available in Thai language only.
WHO Western Pacific Regional Office invited ANPUD in the capacity of temporary advisor to its biennial National HIV, Hepatitis and STI Programme Managers Meeting for Selected Asian and Pacific Countries from 27-30 June 2017 in Manila, Philippines. Mr. Rajiv Kafle, ANPUD’s regional secretariat, delivered the statement on behalf of ANPUD in the meeting.
The report focuses on hepatitis B and C, which are responsible for 96% of all hepatitis mortality. It presents data along the five strategic directions (strategic information, interventions, equity, financing and innovation) – key pillars of the GHSS to facilitate monitoring of progress in countries, regions and globally, and to measure the impact of interventions on reducing new infections and
saving lives between 2015 and 2030.
The tool describes how services can be designed and implemented to be accessible and acceptable to people who inject drugs. This requires respectful and ongoing engagement, and this publication gives particular attention to programmes run in close partnership with, or by, organizations of people who use drugs.
HCV prevalence in Asia and the Pacific varies between countries. HCV infection is due to unsterile medical injections (2 , 3) contaminated blood transfusions, (4) traditional cultural practices60 and, more recently, injecting drug use. (5) While iatrogenic transmission still occurs in some countries, transmission as the result of injecting drug use is increasing. (6)
This is the first-ever global report on treatment access to hepatitis C medicines. The report provides the information that countries and health authorities need to identify the appropriate HCV treatment, and procure it at affordable prices. The report uses the experience of several pioneering countries to demonstrate how barriers to treatment access can be overcome.
Sorry, no posts matched your criteria